S.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country
1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020
DOC: June 2020 Both 18 Yrs. and older Brazil
2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020
DOC:September 2020 Both 18 Yrs. and older Jordan
3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020
DOC: July 2020 Both 18 to75 Yrs. China
4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020
DOC: July 2021 Both 18 to75 Yrs. –
5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020
DOC: December 2021 Both 18 to70 Yrs. China
6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020
DOC: February 2022 Both 18 to 65 Yrs. China
7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs
(MSCs-Exo) DOS: February 2020
DOC: July 2020 Both 18 to75 Yrs. –
8- NCT043
36,254 Safety and Efficacy
Study of Allogeneic
Human Dental Pulp
Mesenchymal Stem
Cells to Treat Severe
COVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020
DOC: March
2021 Both 18 to 65 Yrs. China
9- NCT043
39,660 Clinical Research of Human Mesenchymal
Stem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020
DOC: June 2020 Both 18 to 75 Yrs. China
10- NCT043
46,368 Bone Marrow-Derived
Mesenchymal Stem
Cell Treatment for
Severe Patients With
Coronavirus Disease
2019 (COVID19) I and II Not
Recruiting 20 BM-MSCs DOS: April 2020
DOC: December
2020 Both 18 to 75 Yrs. China
11- NCT043
52,803 Adipose Mesenchymal
Cells for Abatement of
SARS CoV-2
Respiratory
Compromise in
COVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020
DOC: April 2026 Both 18 to 90 Yrs. –
12- NCT043
49,631 A Clinical Trial to
Determine the Safety
and Efficacy of Hope
Biosciences
Autologous
Mesenchymal Stem
Cell Therapy (HBadMSCs)
to Provide
Protection Against
COVID19 II Enrolling by
invitation 56 AD-MSCs DOS: May 2020
DOC: December 2020 Both Child, Adult,
Older
Adult United States
13- NCT030
42,143 Repair of Acute
Respiratory Distress
Syndrome by Stromal
Cell Administration
(REALIST) (COVID19)
(REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019
DOC: October 2022 Both 16 Yrs. and older United Kingdom
14- NCT043
90,152 Safety and Efficacy of Intravenous Wharton’s
Jelly Derived
Mesenchymal Stem
Cells in Acute
Respiratory Distress
Syndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020
DOC: May 2021 Both 18 to 80 Yrs. Colombia
15- NCT043
82,547 Treatment of
COVID19 Associated
Pneumonia with
Allogenic Pooled
Olfactory Mucosaderived
Mesenchymal
Stem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020
DOC: June 2021 Both 18 to70 Yrs. Belarus
16- NCT043
66,323 Clinical Trial to Assess
the Safety and
Efficacy of Intravenous
Administration of Allogeneic Adult
Mesenchymal Stem
Cells of Expanded
Adipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020
DOC: October 2021 Both 18 to 80 Yrs. –
17- NCT043
66,063 Mesenchymal Stem
Cell Therapy for SARS-CoV-2-related
Acute Respiratory
Distress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020
DOC: December 2020 Both 18 to 65 Yrs. Iran
18- NCT043
77,334 Mesenchymal Stem
Cells (MSCs) in Inflammation-
Resolution Programs
of Coronavirus
Disease 2019
(COVID19) Induced
Acute Respiratory
Distress Syndrome
(ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020
DOC: February 2021 Both 18 Yrs. and older Germany
19- NCT043
71,393 MSCs in COVID19
ARDS III Recruiting 300 MSCs
Remestemcel-L DOS: April 30, 2020
DOC: April 2022 Both 18 Yrs. and older United States
20- NCT043
62,189 Efficacy and Safety
Study of Allogeneic
HB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020
DOC: October 2020 Both Child,
Adult,
Older
Adult United States
21- NCT043
66,271 Clinical Trial of
Allogeneic
Mesenchymal Cells
from Umbilical Cord
Tissue in Patients with
COVID19 II Recruiting 106 UC-MSCs DOS: May 2020
DOC: May 2021 Both 40 to 80 Yrs. Spain
22- NCT043
48,435 A Randomized,
Double-Blind,
Placebo-Controlled
Clinical Trial to Determine the Safety and Efficacy of Hope
Biosciences
Allogeneic
Mesenchymal Stem
Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020
DOC: April 2021 Both Child,
Adult, Older
Adult United States
23- NCT043
71,601 Safety and Effectiveness of Mesenchymal Stem
Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020
DOC: December 2022 Both 18 to 70 Yrs. China
24- NCT043
55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020
DOC: May 2021 Both 18 Yrs. and older United States
25- NCT043
92,778 Clinical Use of Stem
Cells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020
DOC: September 2020 Both 40 to 60 Yrs. Turkey
26- NCT043
97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020
DOC: June 2021 Both 18 to 80 Yrs. –
27- NCT043
90,139 Efficacy and Safety
Evaluation of Mesenchymal Stem
Cells for the Treatment of Patients
with Respiratory
Distress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020
DOC: December 2020 Both 18 to 75 Yrs. Spain
28- NCT042
69,525 Umbilical Cord (UC)- Derived Mesenchymal
Stem Cells (MSCs)
Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020
DOC: September 2020 Both 18 to 75 Yrs. China